Article

Synthesis and PET studies of [(11)C-cyano]letrozole (Femara), an aromatase inhibitor drug.

Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA.
Nuclear Medicine and Biology (Impact Factor: 2.41). 03/2009; 36(2):215-23. DOI: 10.1016/j.nucmedbio.2008.11.010
Source: PubMed

ABSTRACT Aromatase, a member of the cytochrome P450 family, converts androgens such as androstenedione and testosterone into estrone and estradiol, respectively. Letrozole (1-[bis-(4-cyanophenyl)methyl]-1H-1,2,4-triazole; Femara) is a high-affinity aromatase inhibitor (K(i)=11.5 nM) that has Food and Drug Administration approval for breast cancer treatment. Here we report the synthesis of carbon-11-labeled letrozole and its assessment as a radiotracer for brain aromatase in the baboon.
Letrozole and its precursor (4-[(4-bromophenyl)-1H-1,2,4-triazol-1-ylmethyl]benzonitrile) were prepared in a two-step synthesis from 4-cyanobenzyl bromide and 4-bromobenzyl bromide, respectively. The [(11)C]cyano group was introduced via tetrakis(triphenylphosphine)palladium(0)-catalyzed coupling of [(11)C]cyanide with the bromo precursor. Positron emission tomography (PET) studies in the baboon brain were carried out to assess regional distribution and kinetics, reproducibility of repeated measures and saturability. Log D, the free fraction of letrozole in plasma and the [(11)C-cyano]letrozole fraction in arterial plasma were also measured.
[(11)C-cyano]Letrozole was synthesized in 60 min with a radiochemical yield of 79-80%, with a radiochemical purity greater than 98% and a specific activity of 4.16+/-2.21 Ci/mumol at the end of bombardment (n=4). PET studies in the baboon revealed initial rapid and high uptake and initial rapid clearance, followed by slow clearance of carbon-11 from the brain, with no difference between brain regions. Brain kinetics was not affected by coinjection of unlabeled letrozole (0.1 mg/kg). The free fraction of letrozole in plasma was 48.9%, and log D was 1.84.
[(11)C-cyano]Letrozole is readily synthesized via a palladium-catalyzed coupling reaction with [(11)C]cyanide. Although it is unsuitable as a PET radiotracer for brain aromatase, as revealed by the absence of regional specificity and saturability in brain regions such as amygdala, which are known to contain aromatase, it may be useful in measuring letrozole distribution and pharmacokinetics in the brain and peripheral organs.

0 Bookmarks
 · 
176 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this paper, a new method is reported for the surface grafting of poly[1-(N,N-bis-carboxymethyl)amino-3-allylglycerol-co-dimethylacrylamide] onto magnetic nano-particles modified by 3-mercaptopropyltrimethoxysilane. The grafted nano-sorbent was characterized by Fourier transform infrared spectroscopy, elemental analysis, thermogravimetric analysis, and scanning electron microscopy. Agglomerated nano-particles with multi-pores were used for extraction and determination of trace letrozole in human biological fluids and pharmaceutical samples. The profile of the letrozole uptake by the magnetic nano-sorbent reflected good accessibility of the active sites in the grafted polymer. Scatchard analysis revealed that the sorption capacity of the functionalized nano-sorbent was 6.27µmolg(-1) at an optimum pH of 4. The equilibrium adsorption data of letrozole by grafted magnetic nano-sorbent were analyzed by Langmuir, Freundlich, Temkin and Redlich-Peterson models. Conformation of the experimental data in the Langmuir isotherm model indicated the homogeneous binding site of functional polymer-grafted magnetic nano-sorbent surface. Nearly 89% of letrozole was released in simulated gastric fluid, pH 1.2, in 2h and 79% in simulated intestinal fluid, pH 7.4, in 30h. These results show the utility of the letrozole loaded- polymer grafted magnetite nano-particles for enteric drug delivery.
    Talanta 12/2013; 117C:511-517. DOI:10.1016/j.talanta.2013.09.015 · 3.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aromatase (an enzyme that converts androgens to estrogens) in the brain is involved in neuroprotection, synaptic plasticity, and regulation of sexual and emotional behaviors. To investigate the physiologic and pathologic importance of aromatase in the brain, including in humans, we here report the development of a novel PET probe for aromatase, (11)C-cetrozole, which allows noninvasive quantification of aromatase expression. (11)C-cetrozole was synthesized by the C-(11)C-methylation method developed by our group. In vitro autoradiography of frozen sections and a binding study with rat brain homogenates were conducted to demonstrate the specific binding and the dissociation constant. PET studies with anesthetized rhesus monkeys were performed to analyze the dynamics in the brain. In vitro and in vivo studies using (11)C-cetrozole showed its superiority in brain aromatase imaging in terms of specificity and selectivity, compared with previously developed (11)C-vorozole. PET studies showed that (11)C-cetrozole had a higher signal-to-noise ratio, providing a sharper image than (11)C-vorozole, because the radioactive metabolite of (11)C-vorozole was taken up into the brain. High specific binding of (11)C-cetrozole was observed in the amygdala and hypothalamus, and we also noted binding in the nucleus accumbens of rhesus monkeys for the first time. These results suggest that PET imaging with newly developed (11)C-cetrozole is suitable for quantifying the expression of brain aromatase in vivo, possibly providing critical information regarding the functional roles of aromatase in human neurologic and emotional disorders.
    Journal of Nuclear Medicine 03/2014; 55(5). DOI:10.2967/jnumed.113.131474 · 5.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective The aim of this study was to examine the effects of testosterone on verbal learning and memory in postmenopausal women.DesignRandomised placebo-controlled trial in which participants were randomized (1:1) to transdermal testosterone gel 300mcg/ day, or identical placebo, for 26 weeks.Patients92 post-menopausal women aged 55-65 years, on no systemic sex hormone therapy.MeasurementsThe primary outcome was the score for the International Shopping List Task (ISLT) of CogState. Secondary outcomes included other CogState domains, the Psychological General Well-Being Index (PGWB) and safety variables.Results89 women, median age 60 years, were included in the primary analysis. Testosterone treatment resulted in statistically significantly better performance for the ISLT (improved verbal learning and memory) compared with placebo, adjusted for age and baseline score (mean difference 1·57; 95%CI 0·13, 3·01) p=0.03). There were no significant differences for other CogState domains or the PGWB scores. At 26 weeks, the median total testosterone was 1·7 nmol/L (interquartile range (IQR) 1·1, 2·4) in the testosterone group and 0·4nmol/L (IQR 0·3, 0·5) in the placebo group.Conclusions The small but statistically significant effect of testosterone treatment on verbal learning and memory in postmenopausal women provides the basis for further clinical trials.This article is protected by copyright. All rights reserved.
    Clinical Endocrinology 04/2014; 81(4). DOI:10.1111/cen.12459 · 3.35 Impact Factor

Preview

Download
3 Downloads
Available from